Atea Pharmaceuticals, Inc.

AVIR

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001593899

SEC filings (opens in a new tab)

No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Atea Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of AVIR: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Q3 2025	Change
Holders	107	115	+8
Shares	52.7M	53.2M	+478.9K (+0.9%)
Value	$189.7M	$154.2M	−$35.5M (−18.7%)

New holders (14)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to AVIR in Q3 2025
Institution	Shares	Value	% of portfolio
Cubist Systematic Strategies, LLC	87,774	$254.5K	0.00%
Citadel Advisors LLC	41,729	$121.0K	0.00%
Certified Advisory Corp	24,500	$71.0K	0.01%
Bluefin Capital Management, LLC	24,216	$70.2K	0.03%
SG Americas Securities, LLC	20,461	$59.0K	0.00%
HRT Financial LP	18,842	$54.0K	0.00%
Jump Financial, LLC	16,007	$46.4K	0.00%
AQR Capital Management LLC	13,410	$38.9K	0.00%
California State Teachers Retirement System	4,774	$13.8K	0.00%
Point72 Asia (Singapore) Pte. Ltd.	3,601	$10.4K	0.00%
Optiver Holding B.V.	990	$2.87K	0.00%
SRS Capital Advisors, Inc.	199	$577	0.00%
Allworth Financial LP	63	$183	0.00%
Cloud Capital Management, LLC	59	$0	0.00%

Sold out (6)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of AVIR in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Almitas Capital LLC	445,386	$1.60M
Walleye Capital LLC	57,759	$207.9K
Deutsche Bank AG	42,967	$154.7K
Oxford Asset Management LLP	40,787	$146.8K
US Bancorp	5,470	$19.7K
Raymond James Financial Inc	400	$1.44K